Dr. Pierre J. MARIE, 65 yrs
1979 D.Sc., Physiology, University of Paris 6, France
1982 Ph.D. (State Doctorate) in Physiology, University of Paris 6, France
1979-1980 Research assistant, Genetics Unit, Shriners Hospital, Montreal, Quebec.
1980-1982 Research Associate, Genetics Unit & Assistant Professor, Department of Experimental Surgery, McGill University, Montreal, Canada.
1982-1990 Research Investigator (1st class) at CNRS, U18 INSERM-UA-CNRS, Paris.
1990-2003 Director of research (2nd class) (Professorship)
& Team Leader at INSERM U349, Lariboisière Hospital, Paris, France.
2004-2010 Director of research (1st class) at CNRS
and Team Leader at U606 INSERM/ University Paris Diderot, Lariboisière Hospital, Paris, France.
2012-2014 Director of research (Exceptional class)
Team Leader at U606 INSERM/ University Paris Diderot, Paris, France.
Master/ Ph.D. Levels: Sciences, health and applications, University Paris Diderot (Paris 7);
Aging, University of Paris 5; Cell and molecular biology, University of Cergy-Pontoise, France
Life sciences, University of Paris 6-EPHE, Paris; European Ph.D. Courses, ECTS
- 26 doctoral students (4 fellowships from Ministry of Research, other fellowships from National (ARC, CNES, DIM) or European associations (ECTS) and personal contracts from private associations.
- 8 post-doctoral students (3 fellowships from European grants (FP6, FP7), 5 from personal grants (CNES, Agence Nationale de la Recherche, Fondation Recherche Médicale, pharmaceutical companies).
- Contracts from FP6 European grants (Genostem: Worblock Leader; and Anabonos), FP7 European grant (Talos) , Inserm National Program (Pro-A) , National French Spatial Agency (CNES) , Inserm/AFM, French Associations (Fondation de l’Avenir, Association Rhumatisme et Travail, Fondation Recherche Médicale), National Research Agency (ANR) and pharmaceutical companies.
- Consulting (advising, expertise): Servier International Institute of Research
1998: Multipotent cell line isolated from the human marrow stroma (INPI: 98 13362; 1998).
2008: Use of agonists of integrin alpha 5 for inducing the osteogenic differentiation of mesenchymal stem cells (08290752.8; 2008).
Biology and pathology of osteoblasts : Pathophysiology, cell signaling, therapies.
- French Society of Clinical Biology Research Award (1984)
- Bone Diseases Research Award, Procter et Gamble France (1989)
- Award, French National Academy of Medicine (2008)
- ASBMR Louis Avioli Award (USA) (2010)
-ECTS Mike Horton Preclinical/Translational Award (2013)
- IBMS harold Copp Award (2015)
Reviewer for: Arch Biochem biophys, Clin Therap, Differentiation, Bone, Calcif Tissue Intern, BBA Mol Cell Res, BMC Molecular Biology, ILAR J, J Endo Invest, biochem J, Cell Res, Eur J Endo, Cloning & Stem Cells, Cells Tissues Organs, Stem Cells & Dev, Stem Cell research, Apoptosis, Clin Cancer Res, Cell Physiol Biochem, BBRC, J Bone Miner Res, Arthritis and Rhum, Osteop Internat, J Cell Physiol, Eur J Cell Biol, J Cell Science, Cell Res, BMC Genomics, Development, Kidney Int, Cloning & Stem Cells, Cells Tissues Organs, Future Medicine, Clin Exp Metastasis, Nucleic Acid Res, Pediat Res, Endocrinology, PloSOne, J Clin Endocr Metab, Genome Biology, Stem Cells Rev & Rep, B J Pharm, BMC Med Genet, Eur J Cell Biol, PlosOne, Stem Cell Res, J Cell Mol Med, Mol Biol Cell, Mol Cell Biol; Science STKE, Aging Cell, Dev Dyn, EMBO Mol Med, Nature Genet, Development, J Cell Biol, J Clin Invest.
Expertise for: the Medical Research Council, Arthritis Research Campaign, The Osteoporosis Society of Canada, the Swiss National Foundation for Scientific Research, The Israel Science Fundation, The Wellcome Trust, The Cancer Research Campaign, the European Spatial Agency (ESA), Guy’ and St Thomas’ Charity, ECTS, Telethon, Vaincre la Mucoviscidose, Arthritis Fundation, Austrian Science Fundation, Croucher Foundation, European Science Foundation, Binational Science Fundation (USA-Israel), ANR Programmes Blanc National et international, Univ of Hong Kong.
Member of committees
- Editorial Boards: Bone (USA); Calcified Tissue International (USA), BoneKey (USA), European Journal of Endocrinology, PloS ONE, Gene
- JBMR Associate Editor (2013-2017)
- Board of Directors, ECTS (2006-2012) and IBMS (2011-2014).
- Chairman: ECTS Grant Committee (2006-2012)
- Vice-President, Scientific Council, Faculty of Medicine, Univ. Paris Diderot (2010-2013)
- Executive Committee of Genostem & Workblock leader (European Consortium, 6th FP) (2004-2007)
- Partner of Anabonos (European Consortium, 6th FP) (2008-2010) and Talos (European Consortium, 7th FP) (2009-2011)
-Member, SVSE2 French National Research Agency (ANR) National and International Review Committees (2011), AERES (2013), ANR review committee (2014)
-Member, Program Committees: ECTS, IBMS, IBMS/Japanese Society for Bone and Mineral Research, JFBTM
- Société Française de Rhumatologie (SFR), International Bone Mineral Society (IBMS); European Calcified Tissue Society (ECTS); American Society for Bone and Mineral Research (ASBMR); European Society of Endocrinology (ESE); American Society of Microbiology (ASM)
- 215 publications in journals such as New Eng J Med, J Clin Invest, Am J Pathol, Am J Physiol, J Clin End Met, Hum Mol Gen, Mol Endo, J Bone Miner Res, J Cell Science, J Cell Biol, J Biol Chem, Cancer Res, PloSOne, Mol Cell Biology, PNAS, Science Sci, Aging Cell.
- 147 reviews and book chapters.
- h-index: 58 (Citations: 10844) (Web of Science 09/2015)
The French National Institute of Health and Medical Research (Inserm) is a public scientific and technological institute which operates under the authority of the Ministry of Health and Ministry of Research. Inserm has 318 research units based in universities and university hospitals. The French National Center for Scientific Research (CNRS) and the Pasteur and Curie Institutes also house Inserm research units to bring laboratories around common objectives.
Our research unit U606 (now UMR1132) entitled “Bones and Joints” is the only Inserm unit devoted to both basic and clinical research in France. This Unit is internationally recognized for its expertise in osteoblast biology, genetics of osteoporosis, osteopetrosis and arthritis. The aim of our Team Osteoblast biology and pathology is to determine the mechanisms involved in normal and pathological conditions and to translate them into therapeutics in bone disorders. The research in this Team led to increase our knowledge in osteoblast biology and in the pathogenesis of osteoporosis and skeletal dysplasias induced by genetic mutations.
The focus of my research activities is on the regulation of bone formation, with particular interest in cell and molecular biology of the osteoblast, the determination of mechanisms involved in metabolic, physical and genetic bone diseases, and the effects of strontium in bone.
My research led to identify abnormalities in osteoblastogenesis in several human metabolic and genetic bone diseases such as osteomalacia, osteoporosis, skeletal dysplasias and osteosarcoma.
- By studying X-linked hypophosphatemic (XLH) osteomalacia and a mouse genetic model of the disease, I have initially shown the respective role of calcium and phosphorus in the defective bone mineralization in this disease, and contributed to the development of an effective therapy (J Clin Invest 1980, J Clin Endo Metab 1981, Am J Physiol 1982, N Eng J Med 1980; 1982, Endocrinology 1982, among other publications)
-By developing ex-vivo cultures of osteoblasts, we identified defective osteoblast function in human osteoporosis (JCEM 1989a; 1989b; JBMR 1999; JCI 1991; JBMR 1992; JCEM 1993) and in animal models of osteopenia induced by ovariectomy or hypokinesia (JBMR 1992; Am J Physiol 1993a; 1993b). We subsequently demonstrated the anabolic effects of growth factors on osteoblasts in vitro (JBMR 1990; JCB 1995; Mol Endo 1995; JBMR 1997; JCP 1997; JBC 1998; JBC 2000; JCB 2001; JBC 2004) and in osteopenic animals (AJP 1990; Endocrinology 1994; JCI 1995; JBMR 2002; Exp Cell Res 2005; Exp Cell Res 2007).
-We identified mechanisms regulating mesenchymal stem cells by local, hormonal and endogenous factors (JCB 1998; CTI 1999, JBMR 1999; JCB 2001, ECR 2005; JCB 2008; AJP 2008; FASEB J 2008; JBC 2009; PNAS 2009; JCB 2010; BMC 2010; JBC 2011; JBMR 2012; Nature Rev End 2013).
- We demonstrated that strontium inhibits bone resorption and favours bone formation in rodents (CTI 1986; Bone 1990), which led to the development of a new anti-osteoporotic drug, strontium ranelate in collaboration with Servier Pharma. We demonstrated the beneficial effect of strontium ranelate on bone formation in vitro and in osteopenic animal models and we identified the mechanisms involved in this effect (JBMR 1993; Bone 1996; Bone 2003, 2006; J Cell Mol Med 2009; JBC 2010; Curr Opin Rhum 2005; Curr Opin Pharm 2006; Osteop Intern 2011; Mol Interv 2010; Aging Cell 2012).
-We identified the mechanisms by which Gsa, FGFR2, Twist and CFTR genetic mutations induce osteoblast dysfunction in human and mouse skeletal dysplasias (HMG 1995; AJP 1997; JCI 1998; ECR 2000, ECR 2001, JBMR 2001a, b; AJP 2001; JCI 2001; HMG 2002, BBRC 2002; JBC 2004a, b; JCS 2005; HMG 2005; AJP 2006; Bone 2008; JCB 2010; HMG 2010; Genes & Dev 2002; Front Oral Biol 2008; Science Signal 2010; HMG 2010; AJP 2012; AJP 2014; JBC 2015).
- Finally, we demonstrated the pro-apoptotic effect of statins, syndecan 2 on osteosarcoma cells and the role of receptor tyrosine kinases with the goal of developing new anticancer drugs (Bone 2005; JCB 2006; CDD 2006; Cancer Res 2007; JPET 2008; JBC 2008; Cancer Res 2010; JBMR 2011; Int J cancer 2011; JBMR 2012a; JBMR 2012b; CDD 2013).
-My current research is focused on the mechanisms underlying the defective bone formation in cystic fibrosis.